Summary

The global Viral Vector Manufacturing CDMO Services market size was US$ 832 million in 2025 and is forecast to reach a readjusted size of US$ 3587 million by 2032 with a CAGR of 23.5% during the forecast period 2026-2032.
Viral Vector Manufacturing CDMO Services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.
The Viral Vector Manufacturing CDMO Services market has emerged as a critical enabler of the rapidly growing gene therapy and advanced biologics sector, driven by the increasing demand for specialized production capabilities and accelerated time-to-market for innovative therapies. The market is characterized by high technological barriers, requiring expertise in viral vector design, process development, cGMP-compliant manufacturing, and quality assurance. Companies in this space are leveraging advanced bioprocessing technologies, automation, and artificial intelligence tools to improve yield, consistency, and scalability while maintaining regulatory compliance. Strategic partnerships between biotechnology firms and CDMOs are becoming increasingly common, allowing developers to outsource complex manufacturing tasks and focus on clinical development and commercialization. Overall, the market is marked by intense competition among specialized service providers, rapid technological innovation, and growing adoption of viral vector-based therapies across diverse therapeutic areas, positioning CDMOs as indispensable partners in the biopharmaceutical value chain.
The global Viral Vector Manufacturing CDMO Services market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
uBriGene
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem
Segment by Type
Adeno-associated Virus
Lentivirus
Adenovirus
HSV
Others
Segment by Application
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Viral Vector Manufacturing CDMO Services market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Viral Vector Manufacturing CDMO Services value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Adeno-associated Virus
1.2.3 Lentivirus
1.2.4 Adenovirus
1.2.5 HSV
1.2.6 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector Manufacturing CDMO Services Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Region (2021-2026)
2.4 Global Viral Vector Manufacturing CDMO Services Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Viral Vector Manufacturing CDMO Services Market Size and Prospective (2021-2032)
2.5.2 Europe Viral Vector Manufacturing CDMO Services Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size and Prospective (2021-2032)
2.5.4 Latin America Viral Vector Manufacturing CDMO Services Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Viral Vector Manufacturing CDMO Services Historical Market Size by Type (2021-2026)
3.2 Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Viral Vector Manufacturing CDMO Services
4 Breakdown Data by Application
4.1 Global Viral Vector Manufacturing CDMO Services Historical Market Size by Application (2021-2026)
4.2 Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Viral Vector Manufacturing CDMO Services Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Viral Vector Manufacturing CDMO Services Players by Revenue (2021-2026)
5.1.2 Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Viral Vector Manufacturing CDMO Services Revenue
5.4 Global Viral Vector Manufacturing CDMO Services Market Concentration Analysis
5.4.1 Global Viral Vector Manufacturing CDMO Services Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing CDMO Services Revenue in 2025
5.5 Global Key Players of Viral Vector Manufacturing CDMO Services Head Offices and Areas Served
5.6 Global Key Players of Viral Vector Manufacturing CDMO Services, Product and Application
5.7 Global Key Players of Viral Vector Manufacturing CDMO Services, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026)
6.1.2.2 North America Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026)
6.1.3.2 North America Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
6.1.4 North America Viral Vector Manufacturing CDMO Services Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026)
6.2.2.2 Europe Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026)
6.2.3.2 Europe Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
6.2.4 Europe Viral Vector Manufacturing CDMO Services Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Viral Vector Manufacturing CDMO Services Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026)
6.4.2.2 Latin America Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026)
6.4.3.2 Latin America Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
6.4.4 Latin America Viral Vector Manufacturing CDMO Services Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Viral Vector Manufacturing CDMO Services Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Company Details
7.1.2 Thermo Fisher Scientific Business Overview
7.1.3 Thermo Fisher Scientific Viral Vector Manufacturing CDMO Services Introduction
7.1.4 Thermo Fisher Scientific Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.1.5 Thermo Fisher Scientific Recent Development
7.2 Lonza
7.2.1 Lonza Company Details
7.2.2 Lonza Business Overview
7.2.3 Lonza Viral Vector Manufacturing CDMO Services Introduction
7.2.4 Lonza Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.2.5 Lonza Recent Development
7.3 Catalent
7.3.1 Catalent Company Details
7.3.2 Catalent Business Overview
7.3.3 Catalent Viral Vector Manufacturing CDMO Services Introduction
7.3.4 Catalent Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.3.5 Catalent Recent Development
7.4 Charles River
7.4.1 Charles River Company Details
7.4.2 Charles River Business Overview
7.4.3 Charles River Viral Vector Manufacturing CDMO Services Introduction
7.4.4 Charles River Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.4.5 Charles River Recent Development
7.5 Merck
7.5.1 Merck Company Details
7.5.2 Merck Business Overview
7.5.3 Merck Viral Vector Manufacturing CDMO Services Introduction
7.5.4 Merck Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.5.5 Merck Recent Development
7.6 SK pharmteco
7.6.1 SK pharmteco Company Details
7.6.2 SK pharmteco Business Overview
7.6.3 SK pharmteco Viral Vector Manufacturing CDMO Services Introduction
7.6.4 SK pharmteco Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.6.5 SK pharmteco Recent Development
7.7 Oxford Biomedica
7.7.1 Oxford Biomedica Company Details
7.7.2 Oxford Biomedica Business Overview
7.7.3 Oxford Biomedica Viral Vector Manufacturing CDMO Services Introduction
7.7.4 Oxford Biomedica Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.7.5 Oxford Biomedica Recent Development
7.8 AGC Biologics（MolMed）
7.8.1 AGC Biologics（MolMed） Company Details
7.8.2 AGC Biologics（MolMed） Business Overview
7.8.3 AGC Biologics（MolMed） Viral Vector Manufacturing CDMO Services Introduction
7.8.4 AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.8.5 AGC Biologics（MolMed） Recent Development
7.9 Gene Universal
7.9.1 Gene Universal Company Details
7.9.2 Gene Universal Business Overview
7.9.3 Gene Universal Viral Vector Manufacturing CDMO Services Introduction
7.9.4 Gene Universal Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.9.5 Gene Universal Recent Development
7.10 Polyplus (Sartorius)
7.10.1 Polyplus (Sartorius) Company Details
7.10.2 Polyplus (Sartorius) Business Overview
7.10.3 Polyplus (Sartorius) Viral Vector Manufacturing CDMO Services Introduction
7.10.4 Polyplus (Sartorius) Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.10.5 Polyplus (Sartorius) Recent Development
7.11 CCRM
7.11.1 CCRM Company Details
7.11.2 CCRM Business Overview
7.11.3 CCRM Viral Vector Manufacturing CDMO Services Introduction
7.11.4 CCRM Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.11.5 CCRM Recent Development
7.12 FUJIFILM Diosynth Biotechnologies
7.12.1 FUJIFILM Diosynth Biotechnologies Company Details
7.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
7.12.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing CDMO Services Introduction
7.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.12.5 FUJIFILM Diosynth Biotechnologies Recent Development
7.13 Biovian
7.13.1 Biovian Company Details
7.13.2 Biovian Business Overview
7.13.3 Biovian Viral Vector Manufacturing CDMO Services Introduction
7.13.4 Biovian Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.13.5 Biovian Recent Development
7.14 Miltenyi Bioindustry
7.14.1 Miltenyi Bioindustry Company Details
7.14.2 Miltenyi Bioindustry Business Overview
7.14.3 Miltenyi Bioindustry Viral Vector Manufacturing CDMO Services Introduction
7.14.4 Miltenyi Bioindustry Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.14.5 Miltenyi Bioindustry Recent Development
7.15 Aldevron
7.15.1 Aldevron Company Details
7.15.2 Aldevron Business Overview
7.15.3 Aldevron Viral Vector Manufacturing CDMO Services Introduction
7.15.4 Aldevron Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.15.5 Aldevron Recent Development
7.16 Takara Bio
7.16.1 Takara Bio Company Details
7.16.2 Takara Bio Business Overview
7.16.3 Takara Bio Viral Vector Manufacturing CDMO Services Introduction
7.16.4 Takara Bio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.16.5 Takara Bio Recent Development
7.17 Yposkesi
7.17.1 Yposkesi Company Details
7.17.2 Yposkesi Business Overview
7.17.3 Yposkesi Viral Vector Manufacturing CDMO Services Introduction
7.17.4 Yposkesi Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.17.5 Yposkesi Recent Development
7.18 Genezen
7.18.1 Genezen Company Details
7.18.2 Genezen Business Overview
7.18.3 Genezen Viral Vector Manufacturing CDMO Services Introduction
7.18.4 Genezen Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.18.5 Genezen Recent Development
7.19 Exthera
7.19.1 Exthera Company Details
7.19.2 Exthera Business Overview
7.19.3 Exthera Viral Vector Manufacturing CDMO Services Introduction
7.19.4 Exthera Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.19.5 Exthera Recent Development
7.20 Flash Therapeutics
7.20.1 Flash Therapeutics Company Details
7.20.2 Flash Therapeutics Business Overview
7.20.3 Flash Therapeutics Viral Vector Manufacturing CDMO Services Introduction
7.20.4 Flash Therapeutics Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.20.5 Flash Therapeutics Recent Development
7.21 VIVEBiotech
7.21.1 VIVEBiotech Company Details
7.21.2 VIVEBiotech Business Overview
7.21.3 VIVEBiotech Viral Vector Manufacturing CDMO Services Introduction
7.21.4 VIVEBiotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.21.5 VIVEBiotech Recent Development
7.22 FinVector
7.22.1 FinVector Company Details
7.22.2 FinVector Business Overview
7.22.3 FinVector Viral Vector Manufacturing CDMO Services Introduction
7.22.4 FinVector Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.22.5 FinVector Recent Development
7.23 uBriGene
7.23.1 uBriGene Company Details
7.23.2 uBriGene Business Overview
7.23.3 uBriGene Viral Vector Manufacturing CDMO Services Introduction
7.23.4 uBriGene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.23.5 uBriGene Recent Development
7.24 Eurogentec
7.24.1 Eurogentec Company Details
7.24.2 Eurogentec Business Overview
7.24.3 Eurogentec Viral Vector Manufacturing CDMO Services Introduction
7.24.4 Eurogentec Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.24.5 Eurogentec Recent Development
7.25 VGXI
7.25.1 VGXI Company Details
7.25.2 VGXI Business Overview
7.25.3 VGXI Viral Vector Manufacturing CDMO Services Introduction
7.25.4 VGXI Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.25.5 VGXI Recent Development
7.26 GenScript ProBio
7.26.1 GenScript ProBio Company Details
7.26.2 GenScript ProBio Business Overview
7.26.3 GenScript ProBio Viral Vector Manufacturing CDMO Services Introduction
7.26.4 GenScript ProBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.26.5 GenScript ProBio Recent Development
7.27 EurekaBio
7.27.1 EurekaBio Company Details
7.27.2 EurekaBio Business Overview
7.27.3 EurekaBio Viral Vector Manufacturing CDMO Services Introduction
7.27.4 EurekaBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.27.5 EurekaBio Recent Development
7.28 Obio Technology
7.28.1 Obio Technology Company Details
7.28.2 Obio Technology Business Overview
7.28.3 Obio Technology Viral Vector Manufacturing CDMO Services Introduction
7.28.4 Obio Technology Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.28.5 Obio Technology Recent Development
7.29 GeneSail Biotech
7.29.1 GeneSail Biotech Company Details
7.29.2 GeneSail Biotech Business Overview
7.29.3 GeneSail Biotech Viral Vector Manufacturing CDMO Services Introduction
7.29.4 GeneSail Biotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.29.5 GeneSail Biotech Recent Development
7.30 VectorBuilder
7.30.1 VectorBuilder Company Details
7.30.2 VectorBuilder Business Overview
7.30.3 VectorBuilder Viral Vector Manufacturing CDMO Services Introduction
7.30.4 VectorBuilder Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.30.5 VectorBuilder Recent Development
7.31 WuXi ATU
7.31.1 WuXi ATU Company Details
7.31.2 WuXi ATU Business Overview
7.31.3 WuXi ATU Viral Vector Manufacturing CDMO Services Introduction
7.31.4 WuXi ATU Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.31.5 WuXi ATU Recent Development
7.32 Ubrigene
7.32.1 Ubrigene Company Details
7.32.2 Ubrigene Business Overview
7.32.3 Ubrigene Viral Vector Manufacturing CDMO Services Introduction
7.32.4 Ubrigene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.32.5 Ubrigene Recent Development
7.33 Porton Biologics
7.33.1 Porton Biologics Company Details
7.33.2 Porton Biologics Business Overview
7.33.3 Porton Biologics Viral Vector Manufacturing CDMO Services Introduction
7.33.4 Porton Biologics Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.33.5 Porton Biologics Recent Development
7.34 Pharmaron
7.34.1 Pharmaron Company Details
7.34.2 Pharmaron Business Overview
7.34.3 Pharmaron Viral Vector Manufacturing CDMO Services Introduction
7.34.4 Pharmaron Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.34.5 Pharmaron Recent Development
7.35 PackGene Biotechnology
7.35.1 PackGene Biotechnology Company Details
7.35.2 PackGene Biotechnology Business Overview
7.35.3 PackGene Biotechnology Viral Vector Manufacturing CDMO Services Introduction
7.35.4 PackGene Biotechnology Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.35.5 PackGene Biotechnology Recent Development
7.36 Hillgene
7.36.1 Hillgene Company Details
7.36.2 Hillgene Business Overview
7.36.3 Hillgene Viral Vector Manufacturing CDMO Services Introduction
7.36.4 Hillgene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.36.5 Hillgene Recent Development
7.37 Asymchem
7.37.1 Asymchem Company Details
7.37.2 Asymchem Business Overview
7.37.3 Asymchem Viral Vector Manufacturing CDMO Services Introduction
7.37.4 Asymchem Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026)
7.37.5 Asymchem Recent Development
8 Viral Vector Manufacturing CDMO Services Market Dynamics
8.1 Viral Vector Manufacturing CDMO Services Industry Trends
8.2 Viral Vector Manufacturing CDMO Services Market Drivers
8.3 Viral Vector Manufacturing CDMO Services Market Challenges
8.4 Viral Vector Manufacturing CDMO Services Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Viral Vector Manufacturing CDMO Services Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Viral Vector Manufacturing CDMO Services Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Viral Vector Manufacturing CDMO Services Revenue Share by Region (2021-2026)
Table 6. Global Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Viral Vector Manufacturing CDMO Services Revenue Share Forecast by Region (2027-2032)
Table 8. Global Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Type (2021-2026)
Table 10. Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Application (2021-2026)
Table 15. Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Viral Vector Manufacturing CDMO Services Applications
Table 18. Global Viral Vector Manufacturing CDMO Services Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Viral Vector Manufacturing CDMO Services Market Share by Players (2021-2026)
Table 20. Global Top Viral Vector Manufacturing CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector Manufacturing CDMO Services as of 2025)
Table 21. Ranking of Global Top Viral Vector Manufacturing CDMO Services Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Viral Vector Manufacturing CDMO Services Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Viral Vector Manufacturing CDMO Services, Headquarters and Area Served
Table 24. Global Key Players of Viral Vector Manufacturing CDMO Services, Product and Application
Table 25. Global Key Players of Viral Vector Manufacturing CDMO Services, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Company (2021-2026)
Table 29. North America Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Viral Vector Manufacturing CDMO Services Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Application (2021-2026) & (US$ Million)
Table 47. Thermo Fisher Scientific Company Details
Table 48. Thermo Fisher Scientific Business Overview
Table 49. Thermo Fisher Scientific Viral Vector Manufacturing CDMO Services Product
Table 50. Thermo Fisher Scientific Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 51. Thermo Fisher Scientific Recent Development
Table 52. Lonza Company Details
Table 53. Lonza Business Overview
Table 54. Lonza Viral Vector Manufacturing CDMO Services Product
Table 55. Lonza Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 56. Lonza Recent Development
Table 57. Catalent Company Details
Table 58. Catalent Business Overview
Table 59. Catalent Viral Vector Manufacturing CDMO Services Product
Table 60. Catalent Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 61. Catalent Recent Development
Table 62. Charles River Company Details
Table 63. Charles River Business Overview
Table 64. Charles River Viral Vector Manufacturing CDMO Services Product
Table 65. Charles River Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 66. Charles River Recent Development
Table 67. Merck Company Details
Table 68. Merck Business Overview
Table 69. Merck Viral Vector Manufacturing CDMO Services Product
Table 70. Merck Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 71. Merck Recent Development
Table 72. SK pharmteco Company Details
Table 73. SK pharmteco Business Overview
Table 74. SK pharmteco Viral Vector Manufacturing CDMO Services Product
Table 75. SK pharmteco Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 76. SK pharmteco Recent Development
Table 77. Oxford Biomedica Company Details
Table 78. Oxford Biomedica Business Overview
Table 79. Oxford Biomedica Viral Vector Manufacturing CDMO Services Product
Table 80. Oxford Biomedica Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 81. Oxford Biomedica Recent Development
Table 82. AGC Biologics（MolMed） Company Details
Table 83. AGC Biologics（MolMed） Business Overview
Table 84. AGC Biologics（MolMed） Viral Vector Manufacturing CDMO Services Product
Table 85. AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 86. AGC Biologics（MolMed） Recent Development
Table 87. Gene Universal Company Details
Table 88. Gene Universal Business Overview
Table 89. Gene Universal Viral Vector Manufacturing CDMO Services Product
Table 90. Gene Universal Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 91. Gene Universal Recent Development
Table 92. Polyplus (Sartorius) Company Details
Table 93. Polyplus (Sartorius) Business Overview
Table 94. Polyplus (Sartorius) Viral Vector Manufacturing CDMO Services Product
Table 95. Polyplus (Sartorius) Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 96. Polyplus (Sartorius) Recent Development
Table 97. CCRM Company Details
Table 98. CCRM Business Overview
Table 99. CCRM Viral Vector Manufacturing CDMO Services Product
Table 100. CCRM Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 101. CCRM Recent Development
Table 102. FUJIFILM Diosynth Biotechnologies Company Details
Table 103. FUJIFILM Diosynth Biotechnologies Business Overview
Table 104. FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing CDMO Services Product
Table 105. FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 106. FUJIFILM Diosynth Biotechnologies Recent Development
Table 107. Biovian Company Details
Table 108. Biovian Business Overview
Table 109. Biovian Viral Vector Manufacturing CDMO Services Product
Table 110. Biovian Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 111. Biovian Recent Development
Table 112. Miltenyi Bioindustry Company Details
Table 113. Miltenyi Bioindustry Business Overview
Table 114. Miltenyi Bioindustry Viral Vector Manufacturing CDMO Services Product
Table 115. Miltenyi Bioindustry Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 116. Miltenyi Bioindustry Recent Development
Table 117. Aldevron Company Details
Table 118. Aldevron Business Overview
Table 119. Aldevron Viral Vector Manufacturing CDMO Services Product
Table 120. Aldevron Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 121. Aldevron Recent Development
Table 122. Takara Bio Company Details
Table 123. Takara Bio Business Overview
Table 124. Takara Bio Viral Vector Manufacturing CDMO Services Product
Table 125. Takara Bio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 126. Takara Bio Recent Development
Table 127. Yposkesi Company Details
Table 128. Yposkesi Business Overview
Table 129. Yposkesi Viral Vector Manufacturing CDMO Services Product
Table 130. Yposkesi Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 131. Yposkesi Recent Development
Table 132. Genezen Company Details
Table 133. Genezen Business Overview
Table 134. Genezen Viral Vector Manufacturing CDMO Services Product
Table 135. Genezen Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 136. Genezen Recent Development
Table 137. Exthera Company Details
Table 138. Exthera Business Overview
Table 139. Exthera Viral Vector Manufacturing CDMO Services Product
Table 140. Exthera Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 141. Exthera Recent Development
Table 142. Flash Therapeutics Company Details
Table 143. Flash Therapeutics Business Overview
Table 144. Flash Therapeutics Viral Vector Manufacturing CDMO Services Product
Table 145. Flash Therapeutics Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 146. Flash Therapeutics Recent Development
Table 147. VIVEBiotech Company Details
Table 148. VIVEBiotech Business Overview
Table 149. VIVEBiotech Viral Vector Manufacturing CDMO Services Product
Table 150. VIVEBiotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 151. VIVEBiotech Recent Development
Table 152. FinVector Company Details
Table 153. FinVector Business Overview
Table 154. FinVector Viral Vector Manufacturing CDMO Services Product
Table 155. FinVector Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 156. FinVector Recent Development
Table 157. uBriGene Company Details
Table 158. uBriGene Business Overview
Table 159. uBriGene Viral Vector Manufacturing CDMO Services Product
Table 160. uBriGene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 161. uBriGene Recent Development
Table 162. Eurogentec Company Details
Table 163. Eurogentec Business Overview
Table 164. Eurogentec Viral Vector Manufacturing CDMO Services Product
Table 165. Eurogentec Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 166. Eurogentec Recent Development
Table 167. VGXI Company Details
Table 168. VGXI Business Overview
Table 169. VGXI Viral Vector Manufacturing CDMO Services Product
Table 170. VGXI Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 171. VGXI Recent Development
Table 172. GenScript ProBio Company Details
Table 173. GenScript ProBio Business Overview
Table 174. GenScript ProBio Viral Vector Manufacturing CDMO Services Product
Table 175. GenScript ProBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 176. GenScript ProBio Recent Development
Table 177. EurekaBio Company Details
Table 178. EurekaBio Business Overview
Table 179. EurekaBio Viral Vector Manufacturing CDMO Services Product
Table 180. EurekaBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 181. EurekaBio Recent Development
Table 182. Obio Technology Company Details
Table 183. Obio Technology Business Overview
Table 184. Obio Technology Viral Vector Manufacturing CDMO Services Product
Table 185. Obio Technology Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 186. Obio Technology Recent Development
Table 187. GeneSail Biotech Company Details
Table 188. GeneSail Biotech Business Overview
Table 189. GeneSail Biotech Viral Vector Manufacturing CDMO Services Product
Table 190. GeneSail Biotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 191. GeneSail Biotech Recent Development
Table 192. VectorBuilder Company Details
Table 193. VectorBuilder Business Overview
Table 194. VectorBuilder Viral Vector Manufacturing CDMO Services Product
Table 195. VectorBuilder Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 196. VectorBuilder Recent Development
Table 197. WuXi ATU Company Details
Table 198. WuXi ATU Business Overview
Table 199. WuXi ATU Viral Vector Manufacturing CDMO Services Product
Table 200. WuXi ATU Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 201. WuXi ATU Recent Development
Table 202. Ubrigene Company Details
Table 203. Ubrigene Business Overview
Table 204. Ubrigene Viral Vector Manufacturing CDMO Services Product
Table 205. Ubrigene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 206. Ubrigene Recent Development
Table 207. Porton Biologics Company Details
Table 208. Porton Biologics Business Overview
Table 209. Porton Biologics Viral Vector Manufacturing CDMO Services Product
Table 210. Porton Biologics Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 211. Porton Biologics Recent Development
Table 212. Pharmaron Company Details
Table 213. Pharmaron Business Overview
Table 214. Pharmaron Viral Vector Manufacturing CDMO Services Product
Table 215. Pharmaron Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 216. Pharmaron Recent Development
Table 217. PackGene Biotechnology Company Details
Table 218. PackGene Biotechnology Business Overview
Table 219. PackGene Biotechnology Viral Vector Manufacturing CDMO Services Product
Table 220. PackGene Biotechnology Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 221. PackGene Biotechnology Recent Development
Table 222. Hillgene Company Details
Table 223. Hillgene Business Overview
Table 224. Hillgene Viral Vector Manufacturing CDMO Services Product
Table 225. Hillgene Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 226. Hillgene Recent Development
Table 227. Asymchem Company Details
Table 228. Asymchem Business Overview
Table 229. Asymchem Viral Vector Manufacturing CDMO Services Product
Table 230. Asymchem Revenue in Viral Vector Manufacturing CDMO Services Business (2021-2026) & (US$ Million)
Table 231. Asymchem Recent Development
Table 232. Viral Vector Manufacturing CDMO Services Market Trends
Table 233. Viral Vector Manufacturing CDMO Services Market Drivers
Table 234. Viral Vector Manufacturing CDMO Services Market Challenges
Table 235. Viral Vector Manufacturing CDMO Services Market Restraints
Table 236. Research Programs/Design for This Report
Table 237. Key Data Information from Secondary Sources
Table 238. Key Data Information from Primary Sources


List of Figures
Figure 1. Viral Vector Manufacturing CDMO Services Product Picture
Figure 2. Global Viral Vector Manufacturing CDMO Services Market Share by Type: 2025 vs 2032
Figure 3. Adeno-associated Virus Features
Figure 4. Lentivirus Features
Figure 5. Adenovirus Features
Figure 6. HSV Features
Figure 7. Others Features
Figure 8. Global Viral Vector Manufacturing CDMO Services Market Share by Application: 2025 vs 2032
Figure 9. Vaccine Development
Figure 10. Gene Therapy
Figure 11. Academic Scientific Research Institution
Figure 12. Others
Figure 13. Viral Vector Manufacturing CDMO Services Report Years Considered
Figure 14. Global Viral Vector Manufacturing CDMO Services Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 15. Global Viral Vector Manufacturing CDMO Services Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Viral Vector Manufacturing CDMO Services Market Share by Revenue, by Region: 2021 vs 2025
Figure 17. North America Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Europe Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Asia-Pacific Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Latin America Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Growth Rate (2021-2032)
Figure 21. Middle East & Africa Viral Vector Manufacturing CDMO Services Revenue (US$ Million) Growth Rate (2021-2032)
Figure 22. Global Viral Vector Manufacturing CDMO Services Market Share by Players in 2025
Figure 23. Global Top Viral Vector Manufacturing CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector Manufacturing CDMO Services as of 2025)
Figure 24. The Top 10 and 5 Players Market Share by Viral Vector Manufacturing CDMO Services Revenue in 2025
Figure 25. North America Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
Figure 26. North America Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
Figure 27. Europe Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
Figure 28. Europe Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
Figure 29. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
Figure 30. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
Figure 31. Latin America Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
Figure 32. Latin America Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
Figure 33. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Type (2021-2026)
Figure 34. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Application (2021-2026)
Figure 35. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 36. Lonza Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 37. Catalent Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 38. Charles River Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 39. Merck Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 40. SK pharmteco Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 41. Oxford Biomedica Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 42. AGC Biologics（MolMed） Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 43. Gene Universal Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 44. Polyplus (Sartorius) Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 45. CCRM Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 46. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 47. Biovian Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 48. Miltenyi Bioindustry Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 49. Aldevron Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 50. Takara Bio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 51. Yposkesi Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 52. Genezen Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 53. Exthera Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 54. Flash Therapeutics Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 55. VIVEBiotech Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 56. FinVector Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 57. uBriGene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 58. Eurogentec Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 59. VGXI Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 60. GenScript ProBio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 61. EurekaBio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 62. Obio Technology Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 63. GeneSail Biotech Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 64. VectorBuilder Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 65. WuXi ATU Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 66. Ubrigene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 67. Porton Biologics Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 68. Pharmaron Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 69. PackGene Biotechnology Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 70. Hillgene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 71. Asymchem Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021-2026)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed